Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study

Wendy L St Peter, Akeem A. Yusuf, Thy Do, Kimberly A. Lowe, Jiannong Liu, Kimberly M. Nieman, Brian D. Bradbury, Allan J. Collins

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. Methods: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for ≥ 40 days. We grouped patients into quartiles of PTH change after first cinacalcet prescription. We used Cox proportional hazard modeling to evaluate associations between short-term PTH change and time to first composite event (hospitalization for cardiovascular events or mortality) within 1 year. Overall models and models stratified by baseline PTH levels were adjusted for several patient-related factors. Results: For 2485 of 3467 included patients (72%), PTH levels decreased after first cinacalcet prescription; for 982 (28%), levels increased or were unchanged. Several characteristics differed between PTH change groups, including age and mineral-and-bone-disorder laboratory values. In adjusted models, we did not identify an association between greater short-term PTH reduction and lower composite event rates within 1 year, overall or in models stratified by baseline PTH levels. Conclusions: Short-term change in PTH levels after first cinacalcet prescription does not appear to be a useful surrogate for longer-term improvements in cardiovascular or survival risk.

Original languageEnglish (US)
Article number41
JournalBMC Nephrology
Volume16
Issue number1
DOIs
StatePublished - Dec 1 2015

Bibliographical note

Publisher Copyright:
© 2015 St. Peter et al.; licensee BioMed Central.

Keywords

  • Cinacalcet
  • Hemodialysis
  • Parathyroid hormone
  • Secondary hyperparathyroidism

Fingerprint

Dive into the research topics of 'Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study'. Together they form a unique fingerprint.

Cite this